{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:23:59Z","timestamp":1792682639055,"version":"4.5.0"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2024.30290","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T15:32:31Z","timestamp":1724686351000},"page":"e2430290","source":"Crossref","is-referenced-by-count":4,"title":["Reinfection After Hepatitis C Virus Treatment\u2014Keep Testing, Keep Treating"],"prefix":"10.1001","volume":"7","author":[{"given":"Marianne","family":"Martinello","sequence":"first","affiliation":[{"name":"Kirby Institute, University of New South Wales, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail V.","family":"Matthews","sequence":"additional","affiliation":[{"name":"Kirby Institute, University of New South Wales, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"issue":"8","key":"zic240168r1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.30024","article-title":"Hepatitis C virus reinfection among people who inject drugs: long-term follow-up of the HERO study.","volume":"7","author":"Litwin","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"7","key":"zic240168r2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S2468-1253(21)00077-7","article-title":"Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.","volume":"6","author":"Hajarizadeh","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"zic240168r3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1473-3099(17)30676-X","article-title":"Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study.","volume":"18","author":"Zelenev","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"zic240168r4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jhep.2021.09.038","article-title":"Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.","volume":"76","author":"Yeung","year":"2022","journal-title":"J Hepatol"},{"issue":"5","key":"zic240168r5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S2468-1253(21)00471-4","article-title":"Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis.","volume":"7","author":"Cunningham","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"zic240168r7","doi-asserted-by":"publisher","first-page":"e673","DOI":"10.1016\/S2214-109X(23)00058-X","article-title":"Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review.","volume":"11","author":"Colledge-Frisby","year":"2023","journal-title":"Lancet Glob Health"},{"key":"zic240168r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103422","article-title":"Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort.","volume":"96","author":"Carson","year":"2021","journal-title":"Int J Drug Policy"},{"issue":"4","key":"zic240168r9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2021.04.056","article-title":"Sofosbuvir\/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.","volume":"75","author":"Matthews","year":"2021","journal-title":"J Hepatol"},{"issue":"4","key":"zic240168r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.0302","article-title":"Changes in use of hepatitis C direct-acting antivirals after access restrictions were eased by state Medicaid programs.","volume":"5","author":"Davey","year":"2024","journal-title":"JAMA Health Forum"},{"key":"zic240168r6","unstructured":"US Food and Drug Administration. FDA permits marketing of first point-of-care hepatitis C RNA test. Published June 27, 2024. Accessed July 8, 2024. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-permits-marketing-first-point-care-hepatitis-c-rna-test"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2822811\/martinello_2024_ic_240168_1723837638.30568.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T07:31:35Z","timestamp":1732692695000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2822811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.30290","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,26]]}}}